RCS - Aptamer Group PLC - Investor Webinar

AptamerAnnouncement

14/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240314:nRSN7789Ga&default-theme=true

RNS Number : 7789G  Aptamer Group PLC  14 March 2024

 REACH: non-regulatory announcement*

 14 March 2024

 Aptamer Group plc

 ("Aptamer" or the "Company")

 Investor Webinar

 Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
 enable innovation in the life sciences industry, announces that Dr. Arron
 Tolley (Chief Technical Officer) and Dr. Adam Hargreaves (Non-Executive
 Director) will be hosting a webinar on Thursday, 21 March 2024 at 5:30pm
 (GMT).

 The webinar will provide investors with a valuable opportunity to interact
 with the Company and gain insights into the recent announcements.

 There will be a Q&A session for investors after the presentation and
 questions can be submitted pre-event as part of the registration process.

 You can register for the event by using the following link:

 www.turnerpope.com/register (http://www.turnerpope.com/register)

 We are delighted to announce that the webinar will be chaired by experienced
 news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com
 (http://www.katiepilbeam.com) ) and hosted by the Company's broker, Turner
 Pope Investments.

Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

 About Aptamer Group plc

 Aptamer Group develops custom affinity binders through its proprietary
 Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
 and research applications. The Company strives to deliver transformational
 solutions that meet the needs of life science researchers and developers.

 Optimer binders are oligonucleotide affinity ligands that can function as an
 antibody alternative. The global affinity ligand market is currently worth
 over US$170 billion.

 Aptamer has successfully delivered projects for a range of global pharma
 companies, diagnostic development companies, and research institutes, covering
 multiple application areas with the objective of establishing royalty-bearing
 licenses.

 This information is provided by Reach, the non-regulatory press release
 distribution service of RNS, part of the London Stock Exchange. Terms and
 conditions relating to the use and distribution of this information may apply.
 For further information, please contact rns@lseg.com or visit www.rns.com
 (http://www.rns.com) .

 RNS may use your IP address to confirm compliance with the terms and
 conditions, to analyse how you engage with the information contained in this
 communication, and to share such analysis on an anonymised basis with others
 as part of our commercial services. For further information about how RNS and
 the London Stock Exchange use the personal data you provide us, please see our
 Privacy Policy.

 END

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over US$170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

This information is provided by Reach, the non-regulatory press release
distribution service of RNS, part of the London Stock Exchange. Terms and
conditions relating to the use and distribution of this information may apply.
For further information, please contact rns@lseg.com or visit www.rns.com
(http://www.rns.com) .

RNS may use your IP address to confirm compliance with the terms and
conditions, to analyse how you engage with the information contained in this
communication, and to share such analysis on an anonymised basis with others
as part of our commercial services. For further information about how RNS and
the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.

 

END

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFLESDELSEDD